Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Transplantation

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    July 2021
  1. BELLI LS, Duvoux C, Cortesi PA, Facchetti R, et al
    COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study.
    Gut. 2021 Jul 19. pii: gutjnl-2021-324879. doi: 10.1136/gutjnl-2021-324879.
    PubMed     Abstract available


    October 2020
  2. ZHANG N, Jiang W, Zhang Y, Song TQ, et al
    Individualised tailored assessment of therapeutic alternatives for HCC patients within the Milan criteria.
    Gut. 2020;69:1893-1895.
    PubMed    


    August 2020
  3. RODRIGUEZ-PERALVAREZ M, Salcedo M, Colmenero J, Pons JA, et al
    Modulating immunosuppression in liver transplant patients with COVID-19.
    Gut. 2020 Aug 18. pii: gutjnl-2020-322620. doi: 10.1136/gutjnl-2020-322620.
    PubMed    


    June 2020
  4. BECCHETTI C, Zambelli MF, Pasulo L, Donato MF, et al
    COVID-19 in an international European liver transplant recipient cohort.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321923. doi: 10.1136/gutjnl-2020-321923.
    PubMed     Abstract available


    March 2020
  5. SCHATTENBERG JM
    Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Gut. 2020 Mar 23. pii: gutjnl-2019-320355. doi: 10.1136/gutjnl-2019-320355.
    PubMed    


  6. BOSCH J, Gracia-Sancho J, Abraldes JG
    Cirrhosis as new indication for statins.
    Gut. 2020 Mar 5. pii: gutjnl-2019-318237. doi: 10.1136/gutjnl-2019-318237.
    PubMed     Abstract available


    December 2019
  7. HARMS MH, de Veer RC, Lammers WJ, Corpechot C, et al
    Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057.
    PubMed     Abstract available


    October 2019
  8. LEE SW, Kwon JH, Lee HL, Yoo SH, et al
    Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Gut. 2019 Oct 31. pii: gutjnl-2019-318947. doi: 10.1136/gutjnl-2019-318947.
    PubMed     Abstract available


    October 2017
  9. KIM GA, Lim YS, Han S, Choi J, et al
    High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Gut. 2017 Oct 21. pii: gutjnl-2017-314904. doi: 10.1136/gutjnl-2017-314904.
    PubMed     Abstract available


    July 2017
  10. DE VRIES EM, Wang J, Williamson KD, Leeflang MM, et al
    A novel prognostic model for transplant-free survival in primary sclerosing cholangitis.
    Gut. 2017 Jul 24. pii: gutjnl-2016-313681. doi: 10.1136/gutjnl-2016-313681.
    PubMed     Abstract available


  11. MELGAR-LESMES P, Balcells M, Edelman ER
    Implantation of healthy matrix-embedded endothelial cells rescues dysfunctional endothelium and ischaemic tissue in liver engraftment.
    Gut. 2017;66:1297-1305.
    PubMed     Abstract available


    April 2017
  12. TRIVEDI PJ, Tickle J, Vesterhus MN, Eddowes PJ, et al
    Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312354. doi: 10.1136/gutjnl-2016-312354.
    PubMed     Abstract available


    March 2017
  13. HERNAEZ R, Sola E, Moreau R, Gines P, et al
    Acute-on-chronic liver failure: an update.
    Gut. 2017;66:541-553.
    PubMed     Abstract available


    August 2015
  14. STOHR S, Costa R, Sandmann L, Westhaus S, et al
    Host cell mTORC1 is required for HCV RNA replication.
    Gut. 2015 Aug 14. pii: gutjnl-2014-308971. doi: 10.1136/gutjnl-2014-308971.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Transplantation is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: